Caris Life Sciences reported revenue of $263.71M and net income of -$1.00M for the quarter ended Jun 2026, up 45.4% year over year. This income statement covers 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||
| Revenue | 100.05M | 101.62M | 129.91M | 120.92M | 181.40M | 216.83M | 292.89M | 216.17M | 263.71M |
| Cost of RevenueCost of Rev | 59.43M | 54.81M | 55.94M | 60.89M | 65.32M | 66.98M | 69.16M | 72.88M | 81.33M |
| Gross Profit | 40.62M | 46.81M | 73.97M | 60.02M | 116.08M | 149.85M | 223.73M | 143.29M | 182.38M |
| Operating items | |||||||||
| Research & DevelopmentR&D | 38.71M | 36.76M | 37.52M | 39.83M | 42.26M | 41.27M | 44.15M | 45.04M | 53.76M |
| Selling, General & AdministrativeSG&A | 41.07M | 40.85M | 43.11M | 52.12M | 64.37M | 51.97M | 56.51M | 59.71M | 66.55M |
| Other Operating ExpensesOther Opex | 87.28M | 84.85M | 86.32M | 86.92M | 92.76M | 90.95M | 103.82M | 106.14M | 116.47M |
| Operating ExpensesOpex | 167.06M | 162.46M | 166.96M | 178.87M | 199.39M | 184.19M | 204.47M | 210.89M | 236.79M |
| Operating IncomeOp. Inc | -67.01M | -60.84M | -37.05M | -57.95M | -17.99M | 32.64M | 88.41M | 5.28M | 26.93M |
| EBIT | -67.01M | -60.84M | -37.05M | -57.95M | -17.99M | 32.64M | 88.41M | 5.28M | 26.93M |
| Non-operating items | |||||||||
| Non Operating Interest Expenses | 13.67M | 13.80M | 13.26M | 12.78M | 19.21M | 13.51M | 11.36M | 12.81M | 9.23M |
| Interest & Investment IncomeInt & Inv Inc | 2.64M | 1.74M | 0.97M | 0.50M | 1.62M | 7.36M | 7.01M | 6.83M | 6.82M |
| Other Non Operating IncomeOther Non Op Inc. | -0.14M | 0.04M | -0.03M | -0.02M | -18.34M | -0.09M | -2.11M | 0.05M | -25.13M |
| Non Operating IncomeNon Op. Inc. | 0.82M | -6.89M | 0.10M | -44.63M | -53.80M | -8.32M | -6.45M | -5.93M | -27.54M |
| Net income details | |||||||||
| EBT | -66.19M | -67.73M | -36.95M | -102.58M | -71.79M | 24.32M | 81.96M | -0.64M | -0.61M |
| Tax ProvisionsTaxes | -0.13M | 0.02M | |||||||
| Profit After TaxPAT | -89.78M | -92.39M | -61.95M | -127.04M | -517.20M | 24.40M | 81.96M | -0.55M | -1.00M |
| Income from Continuing OperationsIncome (Continuing) | -66.19M | -67.73M | -36.95M | -102.58M | -71.79M | 24.32M | 81.96M | -0.51M | -0.64M |
| Consolidated Net IncomeConsol Net Inc. | -66.19M | -67.73M | -36.95M | -102.58M | -71.79M | 24.32M | 81.96M | -0.51M | -0.64M |
| Income towards Parent CompanyParent Net Inc | -66.19M | -67.73M | -36.95M | -102.58M | -71.79M | 24.32M | 81.96M | -0.51M | -0.64M |
| Preferred Dividend PaymentsPref Dividends | 23.59M | 24.66M | 25.00M | 24.46M | 384.44M | ||||
| Net Income towards Common StockholdersNet Income | -89.78M | -92.39M | -61.95M | -127.04M | -517.20M | 24.32M | 81.96M | -0.51M | -0.64M |
| Additional items | |||||||||
| EPS (Basic) | -2.54 | -2.59 | -1.75 | -3.57 | -7.97 | 0.09 | 0.49 | 0.00 | 0.00 |
| EPS (Diluted) | -2.54 | -2.59 | -1.75 | -3.57 | -7.97 | 0.08 | 0.49 | 0.00 | 0.00 |
| Shares Outstanding | 35.37M | 35.64M | 35.50M | 35.62M | 64.92M | 282.10M | 167.21M | 282.56M | 282.89M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 35.37M | 35.64M | 35.50M | 35.62M | 64.92M | 297.21M | 167.21M | 282.56M | 282.89M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 35.42M | 35.82M | 36.50M | 35.24M | 64.92M | 282.10M | 167.21M | 282.65M | 282.58M |
| EBITDA | -67.01M | -60.84M | -37.05M | -57.95M | -17.99M | 32.64M | 88.41M | 5.28M | 26.93M |
| Interest ExpensesInt Expense | 13.67M | 13.80M | 13.26M | 12.78M | 19.21M | 13.51M | 11.36M | 12.81M | 9.23M |
| Tax Rate | 20.81% | -3.75% |